Hypermarcas (OTCMKTS:HYPMY) Trading Down 6.6% - What's Next?

Key Points

• Hypermarcas' share price fell by 6.6% to $4.11 on Friday, with trading volume significantly down by 94% from its average sessions.
• The company received an upgrade to a "strong-buy" rating from Scotiabank, reflecting a positive outlook from analysts.
• For the last quarter, Hypermarcas reported earnings of $0.12 per share with a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price traded down 6.6% during trading on Friday . The company traded as low as $4.11 and last traded at $4.11. 3,629 shares were traded during trading, a decline of 94% from the average session volume of 65,706 shares. The stock had previously closed at $4.40.

Analyst Ratings Changes

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Hypermarcas has an average rating of "Strong Buy".

Hypermarcas Stock Down 6.6%

The firm has a 50 day moving average price of $4.42 and a 200-day moving average price of $4.22. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.63. The firm has a market cap of $2.60 billion, a PE ratio of 19.57 and a beta of 0.86.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share (EPS) for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.